Ibubrofen in the Treatment of Patent Ductus Arteriosus in Preterm Infants: What We Know, What We Still Do Not Know

Current Pharmaceutical Design

Volumn 18, Issue 21, 2012, Pages 3007-3018

  Mercanti, Isabelle ^a   Ligi, Isabelle ^a   Boubred, Farid ^a   Grandvuillemin, Isabelle ^a   Buffat, Christophe ^a   Fayol, Laurance ^a   Millet, Véronique ^a   Simeoni, Umberto ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Ibuprofen; Indomethacin; Ligation; Patent ductus arteriosus; Preterm infant

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; IBUPROFEN; IBUPROFEN LYSINE; INDOMETACIN; NITRIC OXIDE; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR AP 2;

ARTICLE; BLOOD OXYGEN TENSION; BRAIN BLOOD FLOW; BRAIN BLOOD VOLUME; CALCIUM TRANSPORT; CARDIOMEGALY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DUCTUS ARTERIOSUS OBLITERATION; GESTATIONAL AGE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LUNG CIRCULATION; LUNG CLEARANCE; META ANALYSIS (TOPIC); MORTALITY; NEAR INFRARED SPECTROSCOPY; OXYGEN SATURATION; PATENT DUCTUS ARTERIOSUS; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PREMATURITY; PRIORITY JOURNAL; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; THORAX RADIOGRAPHY; VERY LOW BIRTH WEIGHT;

EID: 84862620067     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023007     Document Type: Article

References (132)

1. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld C. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006; 117: 1113-21.
2. Marshall D, Kotelchick M, Young T, Bose C, Kruyer L, O'Shea T. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics 1999; 104: 1345-50.
3. Laughon M, Ma S, Bose C. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated? Curr Opin Pediatr 2004; 16: 146-51.
4. Aranda JV, Thomas R. Systematic review: intravenous Ibuprofen in preterm newborns. Semin Perinatol 2006; 30: 114-20.
5. Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997; 86: 289-93.
6. Chiruvolu A, Jaleel MA. Therapeutic management of patent ductus arteriosus. Early Hum Dev. 2009; 85: 151-5.
7. Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001; 6: 63-73.
8. Clyman RI. Mechanisms regulating the ductus arteriosus. Biol Neonate 2006; 89: 330-35.
9. Hermes-DeSantis ER, Clyman RI. Patent ductus arteriosus: pathophysiology and management. J Perinatol 2006; 26: S14-8.
10. Bökenkamp R, DeRuiter MC, van Munsteren C, Gittenberger-de Groot AC. Insights into the pathogenesis and genetic background of patency of the ductus arteriosus. Neonatology 2010; 98: 6-17.
11. Michelakis ED, Rebeyka I, Wu X, et al. O2 sensing in the human ductus arteriosus. Regulation of voltage-gated K+ channels in smooth muscle cells by a mitochondrial redox sensor. Circ Res 2002; 91: 478-86.
12. Keck M, Resnik E, Linden B, et al. Oxygen increases ductus arteriosus smooth muscle cytosolic calcium via release of calcium from inositol triphosphate-sensitive stores. Am J Physiol Lung Cell Mol Physiol 2005; 288: L917-23.
13. Waleh N, Seidner S, McCurnin D, et al. Anatomic Closure of the Premature Patent Ductus Arteriosus: The Role of CD14+/CD163+ Mononuclear Cells and VEGF in Neointimal Mound Formation. Pediatr Res 2011; 70: 332-338.
14. Herrman K, Bose C, Lewis K, Laughon M. Spontaneous closure of the patent ductus arteriosus in very low birth weight infants following discharge from the neonatal unit. Arch Dis Child Fetal Neonatal Ed 2009; 94: F48-50.
15. Shannon EG, Hansmann H, Hansmann G. Patent ductus arteriosus of the preterm infant. Pediatrics 2010; 125: 1020-30.
16. Costeloe K, Hennessy E, Gibson AT. The EPICure study: outcomes to discharge from hospital for infants born at the threshold of viability. Pediatrics 2000; 106: 659-71.
17. Dagle JM, Lepp TL, Cooper ME, et al. Determination of genetic predisposition to patent ductus arteriosus in preterm infants. Pediatrics 2009; 123: 1116-23.
18. Horbar JD. The Vermont-Oxford Neonatal Network: integrating research and clinical practice to improve the quality of medical care. Semin Perinatol 1995; 19: 124-31.
19. Nemerofsky SL, Parravicini E, Bateman D, Kleinman C, Polin RA, Lorenz JM. The ductus arteriosus rarely requires treatment in infants > 1000 grams. Am J Perinatol 2008; 25: 661-6.
20. Heldt G, Pesonen E, Merritt T, Elias W, Sahn D. Closure of the ductus arteriosus and mechanics of breathing in preterm infants after surfactant replacement therapy. Pediatr Res 1989; 25: 305-10.
21. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000; (2): CD001079.
22. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005; 88: 192-201.
23. Van de Bor M, Verloove-Vanhorick S, Brand R, Ruys J. Patent ductus arteriosus in a cohort of 1338 preterm infants: a collaborative study. Paediatr Perinat Epidemiol 1988; 2: 328-36.
24. Issekutz KA, Graham JM Jr, Prasad C, Smith IM, Blake KD. An epidemiological analysis of CHARGE syndrome: preliminary results from a Canadian study. Am J Genet A 2005; 133A: 309-17.
25. Marino B, Digilio MC, Toscano A, Giannotti A, Dallapiccola B. Congenital heart diseases in children with Noonan syndrome: an expanded cardiac spectrum with high prevalence of atrioventricular canal. J Pediatr 1999; 135: 703-6.
26. Morris CD. Epidemiology of congenital heart disease; in Crawford MH, Di Marco JP (eds): Cardiology. London, Mosby, 2001, chapt 7, pp1.1-1.8.
27. Treszl A, Szabo M, Dunai G et al. Angiotensin II type 1 receptor A1166C polymorphism and prophylactic indomethacin treatment induced ductus arteriosus closure in very low birth weight neonates. Pediatr Res 2003; 62: 753-55.
28. Bhandari V, Zhou G, Bizzarro MJ, et al. Genetic contribution to patent ductus arteriosus in the premature newborn. Pediatrics 2009; 123: 669-73.
29. Evans N. Diagnosis of patent ductus arteriosus in the preterm newborn. Arch Dis Child 1993; 68: 58-61.
30. Evans N, Moorcraft J. Effect of patency of the ductus arteriosus on blood pressure in very preterm infants. Arch Dis Child 1992; 67: 1169-73.
31. Davis P, Turner-Gomes S, Cunningham K, Way C, Roberts R, Schmidt B. Precision and accuracy of clinical and radiological signs in premature infants at risk of patent ductus arteriosus. Arch Pediatr Adolesc Med 1995; 149: 1136-41.
32. Kupferschmid C, Lang D, Pohlandt F. Sensitivity, specificity and predictive value of clinical findings, m-mode echocardiography and continuous-wave Doppler sonography in the diagnosis of symptomatic patent ductus arteriosus in preterm infants. Eur J Pediatr 1988; 147: 279-82.
33. Skelton R, Evans N, Smythe J. A blinded comparison of clinical and echocardiographic evaluation of the preterm infant for patent ductus arteriosus. J Paediatr Child Health 1994; 30: 406-11.
34. Huhta JC. Patent ductus arteriosus in the preterm neonate. In: WA long, Editor, Fetal and Neonatal Cardiology. Philadelphia: WB Saunders 1990: 389-400.
35. Kluckow M, Evans N. Early echographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr 1995; 127: 774-9.
36. Sehgal A, Mc Namara PJ. Does echocardiography facilitate determination of hemodynamic significance attributable to the ductus arteriosus. Eur J Pediatr 2009; 168: 907-14.
37. Su BH, Watanabe T, Shimizu M, Yanagisawa M. Echocardiographic assessment of patent ductus arteriosus shunt flow pattern in premature infants. Arch Dis Child Fetal Neonatal Ed 1997; 77: F36-40.
38. El Hajjar M, Vaksmann G, Rakza T, Kongolo G, Storme L. Severity of the ductal shunt: a comparison of different markers. Arch Dis Child Fetal Neonatal Ed 2005; 90: F419-22.
39. Kwinta P, Rudzinski A, Kruczek P, Kordon Z. Can early echographic findings predict patent ductus arteriosus? Neonatology 2009; 95: 141-8.
40. Mc Namara PJ, Sehgal A. Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed 2007; 92: F424-7.
41. Farombi-Oghuvbu I, Matthews T, Mayne PD, Guerin H, Corcoran JD. N-terminal pro-B-type natriuretic peptide: a measure of significant patent ductus arteriosus. Arch Dis Child Fetal Neonatal Ed 2008; 93: F257-60.
42. Choi BM, Lee KH, Eun BL, et al. Utility of rapid B-type natriuretic peptide assay for diagnosis of symptomatic patent ductus arteriosus in preterm infants. Pediatrics 2005; 115: e255-61.
43. Sanjeev S, Pettersen M, Lua J, Thomas R, Shankaran S, L'Ecuyer T. Role of plasma B-natriuretic peptide in screening for hemodinamically significant patent ductus arteriosus in preterm neonates. J Perinatol 2005; 25: 709-13.
44. Nuntnarumit P, Khositseth A, Thanomsingh P. N-terminal probrain natriuretic peptide and patent ductus arteriosus in preterm infants. J Perinatol 2009; 29: 137-42.
45. Kalra VK, Debari VA, Zauk A, Kataria P, Myridakis D, Kiblawi F. Point-of-Care Testing for B-type Natriuretic Peptide in Premature Neonates with Patent Ductus Arteriosus. Ann Clin Lab Sci 2011; 41: 131-7.
46. Underwood MA, Milstein JM, Sherman MP. Near-infrared spectroscopy as a screening tool for patent ductus arteriosus in extremely low birth weight infants. Neonatology 2007; 91: 134-9.
47. Lemmers PM, Toet MC, van Bel F. Impact of patent ductus arteriosus and subsequent therapy with indomethacin on cerebral oxygenation in preterm infants. Pediatrics 2008; 121: 142-7.
48. Rojas M, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr 1995; 126: 605-10
49. Krauss A, Fatica N, Lewis B, et al. Pulmonary function in preterm infants following treatment with intravenous indomethacin. Am J Dis Child 1989; 143: 78-81.
50. Farstad T, Bratlid D. Pulmonary effects of closure of patent ductus arteriosus in premature infants with severe respiratory distress syndrome. Eur J Pediatr 1994; 153: 903-5.
51. Stefano J, Abbasi S, Pearlman S, Spear M, Esterly K, Bhutani V. Closure of the ductus arteriosus with indomethacin in ventilated neonates with respiratory distress syndrome. Effects of pulmonary compliance and ventilation. Am Rev Respir Dis 1991; 143: 236-9.
52. Yeh T, Thalji A, Luken L, Lilien L, Carr I, Pildes R. Improved lung compliance following indomethacin therapy in premature infants with persistent ductus arteriosus. Chest 1981; 80: 698-700.
53. Gerhardt T, Bancalari E. Lung compliance in newborns with patent ductus arteriosus before and after surgical ligation. Biol Neonate 1980; 38: 96-105.
54. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996; 128: 470-8.
55. Dollburg S, Lusky A, Reichman B. Patent ductus arteriosus, indomethacin and necrotising enterocolitis in very low birth weight infants: a population based-study. J Pediatr Gastroenterol Nutr 2005; 40: 184-8.
56. Bomelburg T, Jorch G. Abnormal blood flow patterns in renal arteries of small preterm infants with patent ductus arteriosus detected by Doppler ultrasonography. Eur J Pediatr 1989; 148: 660-64.
57. Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 1996; 75: F183-6.
58. Pladys P, Beuchee A, Wodey E, Treguier C, Lassel L, Betremieux P. Patent ductus arteriosus and cystic periventricular leucomalacia in preterm infants. Acta Paediatr 2001; 90: 309-15.
59. Noori S, Mc Coy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants. Pediatrics 2009; 123: e138-44.
60. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med 1976; 295: 526-9.
61. Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med 1976; 295: 530-3.
62. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards A. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000; 47: 36-42.
63. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733-8.
64. Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674-81.
65. Lago P, Bettiol T, Salvadori S, Pitassi I, Vianello A, Chiandetti L, Saia OS. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial. Eur J Pediatr 2002; 161: 202-7.
66. Thomas R, Parker G, Van Overmeire B, Aranda JV. A metaanalysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus. Eur J Pediatr 2005; 164: 135-40.
67. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010; (4): CD003481.
68. Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997; 131: 549-54.
69. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards A. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000; 47: 36-42.
70. Naulaers G, Delanghe G, Allegaert K, et al. Ibuprofen and cerebral oxygenation and circulation. Arch Dis Child Fetal Neonatal Ed 2005; 90: F75-6.
71. Giniger RP, Buffat C, Milet V, U. Renal effects of ibuprofen for the treatment of patent ductus arteriosus. J Matern Fetal Neonatal Med 2007; 20: 275-83.
72. Vieux R, Desandes R, Boubred F, et al. Ibuprofen in very preterm infants impairs renal function for the first month of life. Pediatr Nephrol 2010; 25: 267-74.
73. Varvarigou A, Badin CL, Beharry K, Chemtob S, Papageorgiou A, Aranda JV. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants. JAMA 1996; 275: 539-44.
74. Chemtob S, Beharry K, Barna T, Varma DR, Aranda JV. Differences in the effects in the newborn piglets of various nonsteroidal antiinflammatory drugs on cerebral blood flow but not on cerebrovascular prostagland. Pediatr Res 1991; 30: 106-11.
75. Gournay V, Savagner C, Thiriez G, Kuster A, Roze J. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet 2002; 359: 1486-8.
76. Rao R, Bryowsky K, Mao J, Bunton D, McPherson C, Mathur A. Gastrointestinal complications associated with ibuprofen therapy for patent ductus arteriosus. J Perinatol 2011; 31: 465-70.
77. Aranda JV, Varvarigou A, Beharry K, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr 1997; 86: 289-93.
78. Aranda JV, Clyman R, Cox B, et al. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants. Am J Perinatol 2009; 26: 235-45.
79. Durrmeyer X, Hovhannisyan S, Médard Y, et al. Are cytochrome P450 CYP2C8 and CYP2C9 polymorphisms associated with ibuprofen response in very preterm infants? PLoS One 2010; 5: e12329.
80. Gregoire N, Gualano V, Geneteau A, et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. J Clin Pharmacol 2004; 44: 1114-24.
81. Gregoire N, Desfrere L, Roze JC, Kibleur Y, Koehne P. Population pharmacokinetic analysis of Ibuprofen enantiomers in preterm newborn infants. J Clin Pharmacol 2008; 48: 1460-8.
82. Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther 2001; 70: 336-43.
83. Hirt D, Van Overmeire B, Treluyer JM, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol 2008; 65: 629-36.
84. Diot C, Kibleur Y, Desfrere L. Effect of ibuprofen on bilirubinalbumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus. Early Hum Dev 2010; 86: 315-7.
85. Amin SB, Miravalle N. Effect of ibuprofen on bilirubin-albumin binding affinity in premature infants. J Perinat Med 2011; 39: 55-8.
86. Desfrere L, Thibaut C, Kibleur Y, Barbier A, Bordarier C, Moriette G. Unbound bilirubin does not increase during ibuprofen treatment of patent ductus arteriosus in preterm infants. J Pediatr 2011 Aug 27. [Epub ahead of print]
87. Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med 2009; 22 Suppl 3: 88-91.
88. Brooks J, Travadi J, Patole S, Doherty D, Simmer K. Is surgical ligation of patent ductus arteriosus necessary? The western Australian experience of conservative management. Arch Dis Child Fetal Neonatal Ed 2005; 90: F235-9.
89. Van Overmeire B, Follens I, Hartmann S, Creten WL, Van Acker KJ. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neanatal Ed 1997; 76: F179-84.
90. Quinn D, Cooper B, Clyman RI. Factors associated with permanent closure of the ductus arteriosus: a role for prolonged indomethacin therapy. Pediatrics 2002; 110: e10.
91. Van Overmeire B, Chemtob S. The pharmacologic closure of the patent ductus arteriosus. Semin Fetal Neonatal Med 2005; 10: 177-84.
92. Weiss H, Cooper B, Brook M, Sclueter M, Clyman RI. Factors determining reopening of the ductus arteriosus after successful clinical closure with indomethacin. J Pediatr 1995; 127: 466-71.
93. Dani C, Bertini G, Corsini I, et al. The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr 2008; 97: 1176-80.
94. Desfrere L, Zohar S, Morville P, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther 2005; 30: 121-32.
95. Heyman E, Morag I, Batash D, Keidar R, Baram S, Berkovitch M. Closure of patent ductus arteriosus with oral ibuprofen suspension in premature newborns: a pilot study. Pediatrics 2003; 112: e354.
96. Aly H, Lotfy W, Badrawi N, Ghawas M, Abdel-Meguid IE, Hammad TA. Oral Ibuprofen and ductus arteriosus in premature infants: a randomized pilot study. Am J Perinatol 2007; 24: 267-70.
97. Cherif A, Khrouf N, Jabnoun S, Mokrani et al. Randomized pilot study comparing oral ibuprofen with intravenous ibuprofen in very low birth weight infants with patent ductus arteriosus. Pediatrics 2008; 122: e1256-61.
98. Gokmen T, Erdeve O, Altug N, Oguz SS, Uras N, Dilmen U. Efficacy and safety of oral versus intravenous ibuprofen in very low birth weight preterm infants with patent ductus arteriosus. J Pediatr 2011; 158: 549-54.
99. Raju NV, Bharadwaj RA, Thomas R, Konduri GG. Ibuprofen use to reduce the incidence and severity of bronchopulmonary dysplasia: a pilot study. J Perinatol 2000; 20: 13-6.
100. Sharma PK, Garg SK, Narang A. Pharmacokinetics of oral ibuprofen in premature infants. J Clin Pharmacol 2003; 43: 968-73.
101. Gouyon JB, Kibleur Y. Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants. Clin Ther 2010; 32: 1740-8.
102. Mercanti I, Boubred F, Simeoni U. Therapeutic closure of the ductus arteriosus: benefits and limitations. J Matern Fetal Neonatal Med 2009; 22 Suppl 3: 14-20.
103. Jaillard S, Larrue B, Rakza T, Magnenant E, Warembourg H, Storme L. Consequences of delayed surgical closure of patent ductus arteriosus in very premature infants. Ann Thorac Surg 2006; 81: 231-5.
104. Niinikoski H, Alanen M, Parvinen T, Aantaa R, Ekblad H, Kero P. Surgical closure of patent ductus arteriosus in very-low-birthweight infants. Pediatr Surg Int 2001; 17: 338-341.
105. Mosalli R, AlFaleh K. Prophylactic surgical ligation of patent ductus arteriosus for prevention of mortality and morbidity in ex tremely low birth weight infants. Cochrane Database Syst Rev 2008; 1: CD006181.
106. Gersony W, Peckham G, Ellison R, Miettinen O, Nadas A. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr 1983; 102: 895-906.
107. Vida VL, Lago P, Salvadori S, et al. Is there an optimal timing for surgical ligation of patent ductus arteriosus in preterm infants? Ann Thorac Surg 2009; 87: 1509-16.
108. Mikhail M, Lee W, Toews W, et al. Surgical and medical experience with 734 premature infants with patent ductus arteriosus. J Thorac Cardiovasc Surg 1982; 83: 349-57.
109. Sørensen CM, Steensberg JN, Greisen G. Surgical ligation of patent ductus arteriosus in premature infants. Dan Med Bull 2010; 57: A4160.
110. Naik-Mathuria B, Chang S, Fitch ME, et al. Patent ductus arteriosus ligation in neonates: preoperative predictors of poor postoperative outcomes. J Pediatr Surg 2008; 43: 1100-5.
111. Vanderhaegen J, De Smet D, Meyns B, Van De Velde M, Van Huffel S, Naulaers G. Surgical closure of the patent ductus arteriosus and its effect on cerebral tissue oxygenation. Acta Paediatr 2008; 97: 1640-4.
112. Kabra N, Schmidt B, Roberts R, Doyle L, Papile L, Fanaroff A. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results of the trial of indomethacin prophylaxis in preterms. J Pediatr 2007; 150: 229-34.
113. Madan J, Kendrick D, Hagadorn J, Frantz I. Patent ductus arteriosus: impact on neonatal and 18-month outcome. Pediatrics 2009; 123: 674-81.
114. Chorne N, Leonard C, Piecuch R, Clyman R. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics 2007; 119: 1165-74.
115. Schmidt B, Roberts R, Fanaroff A, et al. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the trial of indomethacin prophylaxis in preterms (TIPP). J Pediatr 2006; 148: 730-4.
116. Fowlie PW, Davis PG, McGuire W. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev 2010; 7: CD000174.
117. Van Overmeire B, Allegaert K, Casaer P, et al. Prophylactic ibuprofen in premature infants: a multicentre, randomised, doubleblind, placebo-controlled trial. Lancet 2004; 364: 1945-9.
118. Gournay V, Roze J, Kuster A, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1939-44.
119. Dani C, Bertini G, Pezzati M, et al. Prophylactic ibuprofen for the prevention of intraventricular haemorrhage among preterm infants: a multicenter, randomized study. Pediatrics 2005; 115: 1529-35.
120. Cassady G, Crouse DT, Kirklin JW, et al. A randomized, controlled trial of very early prophylactic ligation of the ductus arteriosus in babies who weighed 1000 g or less at birth. N Engl J Med 1989; 320: 1511-6.
121. Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006; (1): CD004213.
122. Van Overmeire B, Van de Broek H, Van Laer P, Weyler J, Vanhaesebrouck P. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr 2001; 138: 205-11.
123. Benitz WE. Treatment of persistent patent ductus arteriosus in preterm infants: time to accept the null hypothesis? J Perinatol 2010; 30: 241-52.
124. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010 14; (4): CD003481.
125. Vanhaesebrouck S, Zonnenberg I, Van Dervoort P, Bruneel E, Van Hoestenberghe M, Theyskens C. Conservative treatment for patent ductus arteriosus in the preterm. Arch Dis Child Fetal Neonatal Ed 2007; 92: F244-7.
126. Jhaveri N, Moon-Grady A, Clyman RI. Early surgical ligation versus a conservative approach for management of patent ductus arteriosus that fails to close after indomethacin treatment. J Pediatr 2010 Sep; 157: 381-7.
127. Bose CL, Laughon ML. Patent ductus arteriosus: lack of evidence for common treatments. Arch Dis Child Fetal Neonatal Ed 2007; 92: F498-502.
128. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196: 147. e1-8.
129. Benitz WE. Learning to live with patency of the ductus arteriosus in preterm infants. J Perinatol 2011; 31: S42-8.
130. Laughon M, Bose C, Clark R. Treatment strategies to prevent or close a patent ductus arteriosus in preterm infants and outcomes. J Perinatol 2007; 27: 164-70.
131. Chiruvolu A, Jaleel MA. Therapeutic management of patent ductus arteriosus. Early Hum Dev 2009; 85: 151-5.
132. Sweet DG, Carnielli V, Greisen G, et al. European Association of Perinatal Medicine. European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants-2010 update. Neonatology 2010; 97: 402-17